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Mônica M. teixeira  1,4*, Valéria M. A. passos1,4, Sandhi M. Barreto1, Maria I. Schmidt2, 
Bruce B. Duncan2, Alline M. R. Beleigoli1,6, Maria J. M. fonseca3, Pedro G. Vidigal1, 
Larissa f. Araújo5 & Maria de fátima H. S. Diniz1
Diabetes has been associated with cognitive changes and an increased risk of vascular dementia and 
Alzheimer’s disease, but it is unclear whether there are associations between diabetes and early 
alterations in cognitive performance. The present study consisted of a cross-section analysis of 14,444 
participants aged 35–74 years and from a developing country at baseline in the Brazilian Longitudinal 
Study of Adult Health (ELSA–Brasil); these participants were recruited between 2008 and 2010. We 
investigated whether there was an association between diabetes and early changes in the cognitive 
performance of this Brazilian population. To assess cognitive domains, we used the word-list learning, 
word-list delayed recall and word recognition tests along. Phonemic verbal fluency tests included 
semantic phonemic test (animals) and a phonemic test (words beginning with the letter f). executive 
functions associated with attention, concentration and psychomotor speed were evaluated using 
the Trail Making Test B. The exposure variable in the study was defined as diabetes. Multiple linear 
regression was used to estimate the association between diabetes and cognitive performance. the 
results were adjusted for age, sex, education, hypertension, coronary disease, depression, physical 
activity, smoking, alcohol consumption, and the cholesterol/HDL-C ratio. We found a significant 
association between diabetes and decreased memory, language and executive function (attention, 
concentration and psychomotor speed) performance in this population from a country with a distinct 
epidemiological profile, even after adjusting for the main intervening variables.
The world population is ageing, and the incidence of neurodegenerative diseases associated with age is increas-
ing. Diabetes mellitus (diabetes) has been associated with cognitive changes and an increased risk of vascular 
dementia1 and Alzheimer’s disease2. The number of people diagnosed with diabetes worldwide is approximately 
422 million individuals3. Cognitive dysfunction in individuals with diabetes can result from interactions between 
inherent metabolic abnormalities, such as hyperglycaemia, hyperinsulinaemia, and micro- and macrovascular 
complications, in addition to hypertension, dyslipidaemia, depression and obesity4–7. The precise mechanisms 
involved in degenerative diseases in patients with diabetes are unknown and not fully understood; thus, they are 
considered quite complex and dynamic8.
Some studies show a worse performance in cognitive tests among patients with diabetes than among indi-
viduals without diabetes, with deficits in several domains, especially executive function, memory, psychomotor 
speed and attention9,10. A systematic review that included case-control and population-based studies showed 
that the risk of overall cognitive dysfunction was increased in people with diabetes in five of seven cohorts. In 
addition, the association of decreased cognitive performance in one or more domains in was reported in 13 of 
the 20 cross-sectional studies and in five of the seven longitudinal studies included in this review11. According 
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to Berg et al., the association between diabetes and cognition differed among the domains; the processing speed 
was significantly affected in 63% of the studies; attention, in 50%; memory, in 44%; cognitive flexibility, in 38%; 
one language, 33% and general intelligence in 31%11. These functions are particularly relevant because they 
involve behaviours such as problem solving, judgement, and changing habits. All these functions are important 
in prescribing complex tasks, such as aligning the insulin dose with the carbohydrate content, predicting the 
impact of physical activity on blood glucose, or even recognizing and treating hypoglycaemia and hyperglycaemia 
appropriately12,13.
Many studies have investigated the association of diabetes and cognition only in elderly populations2,5,7. 
Recognizing early changes in cognition tests in patients with diabetes may be important for potential future inter-
ventions that help mitigate unfavourable consequences, thereby improving the management of these problems.
This study has the purpose of assessing whether there is an association between cognitive test performance 
and diabetes at baseline in a large cohort of young and middle-aged individuals in a developing country that has 
been experiencing a sociodemographic and nutritional transition in the last three decades. The relevance of this 
study deserves to be highlighted; this is a Latin American cohort, and there are increasing incidence rates of dia-
betes and cognitive impairment in middle and low-income countries14.
Material and Methods
Study population and ethics. The present study is a subproject of the Longitudinal Study of Adult Health 
(ELSA–Brasil). The baseline data was collected from 2008 to 2010 in public universities and research institu-
tions in six Brazilian capitals: the Universidade Federal da Bahia (UFBA), Universidade Federal de Minas Gerais 
(UFMG), Centro Federal de Educação Tecnológica de Minas Gerais (CEFET-MG), Universidade Federal do 
Espírito Santo (UFES), Fundação Oswaldo Cruz (FIOCRUZ), Universidade de São Paulo (USP) and Universidade 
Federal do Rio Grande do Sul (UFRGS). The purpose of the ELSA-Brasil study was to investigate the risk factors 
and incidence of chronic diseases, especially diabetes and cardiovascular diseases15. The data collection was per-
formed via face-to-face interviews, anthropometric measures, arterial pressure and laboratorial tests in the six 
research centres16.
The baseline ELSA-Brasil cohort included 15,105 individuals aged between 35 and 74 years; 54.3% were 
women, 17.3% had diabetes, 35.4% had hypertension, 22.9% were obese, and 40.2% were overweight. In the pres-
ent analysis, 184 participants were excluded due to a previous history of stroke; 330 were excluded due to their use 
of antiepileptic medications, neurotropic agents, or psychotropic agents that could interfere in the cognitive tests; 
and 108 were excluded due to a glycated haemoglobin (A1c) level below 4.0%. We excluded 39 patients with type 
1 diabetes. The remaining final sample size was 14,444 individuals (Fig. 1).
All participants signed the free informed consent form from the ELSA-Brasil study. This study was approved 
by the Ethics and Research Committees of all institutions, including the Research Ethics Committee of the 
Federal University of Minas Gerais, Belo Horizonte (ETIC 186/06), and the National Research Ethics Committee. 
This study was approved by the National Commission of Ethics in Research (CONEP), and all methods were 
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Figure 1. The process of selection of the study population.
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tests of cognitive function (response variables). Cognitive performance was assessed using inter-
nationally standardised tests. The Brazilian version of the learning, recall and word recognition test of the 
Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) includes a list of ten unconnected words 
that was showed to the participant. Immediately afterwards, the participant had to recall as many words as pos-
sible. This procedure was performed three times to evaluate immediate recall (word-list learning). This test eval-
uates the retention of learned words by delayed recall after approximately five minutes, during a second phase 
of the test. Word recognition was assessed by a list of 20 words (ten from the initial stage mixed with ten other 
words). Participants had to recognise the greatest possible number of words from the initial phase (word recog-
nition test). Memory is a sum of learning, recall and word recognition tests17.
Verbal fluency was assessed by tests that evaluate language, memory and executive functions. Verbal fluency 
tests include a semantic phonemic test (animals) and a phonemic test (words beginning with the letter F). These 
tests ask the participant to say all the words related to the category (animals) and beginning with the letter F that 
they can remember within one minute, with final scoring following standardization rules17.
Executive functions associated with attention, concentration and psychomotor speed were evaluated using 
the Trail Making Test B, which requires the participant to draw a line connecting numbers and words as quickly 
as possible without lifting the pencil from the paper. The task execution time is then noted17. Version A of Trail 
Making Test B was used as training for version B (Trail B), as pre-tests revealed that many participants had diffi-
culty understanding this task17–21.
Diabetes (explanatory variable). Samples were collected after a 12-hour fast, stored in a freezer at −80 °C 
and sent to the certified central laboratory in São Paulo. An oral glucose tolerance test (OGTT) was administered 
to all participants without a known diabetes diagnosis [15]. Glycaemia was measured using the enzymatic color-
imetric method (ADVIA 1200 Siemens Deerfield, IL, USA), and glycated haemoglobin A1c was measured using 
high-pressure chromatography (HPLC - Bio-Rad Laboratories, Hercules, CA, USA).
Diabetes was defined as A1c ≥ 6.5% (48 mmol/mol), fasting glycaemia ≥ 126 mg/dL (7.0 mmol/L), or 
OGTT ≥ 200 mg/dL (11.1 mmol/L), according to the American Diabetes Association (ADA) criteria; by insulin 
and antidiabetic drug use; or by the self-reported medical diagnosis of diabetes.
covariates. We investigated and categorised sociodemographic variables such as age, sex and education. 
Age was grouped as follows: 35 to 44, 45 to 54, 55 to 64 and ≥65 to 75 years old. Education was divided into 
four sub-groups: <8 years (incomplete fundamental school), eight years (complete fundamental school), 9–11 
years (high school) and ≥12 years (university degree)22. Leisure time physical activity was assessed using the 
long modified version of the International Physical Activity Questionnaire (IPAQ) and was categorised as low, 
moderate and high23. Smoking status was categorised as never, former, and current smoker. Alcohol use was 
categorised as low (weekly consumption ≤175 g), moderate (176–350 g weekly consumption) and high (>350 g 
weekly consumption).
To assess adiposity, we used anthropometric data and applied standardised techniques and equipment. Weight 
(kg) and height (m) were measured with the participant barefoot and wearing light clothes using a Toledo™ scale 
(accuracy 100 g) and a stadiometer (accuracy 0.1 cm), respectively. Body mass index was also determined [weight 
(kg)/height (m2)]. Abdominal circumference (midpoint between the last rib and the iliac crest) was measured 
using an inelastic tape (cm), and the average of two measures was used in the analysis. The measures were con-
firmed by trained and certified study personnel according to the standards of the project24.
Arterial hypertension was defined by a self-reported medical diagnosis of hypertension, use of 
anti-hypertensive drugs, or blood pressure ≥140/90 mmHg at the time of evaluation (sum of two measures). 
Coronary heart disease was defined as a history of myocardial revascularization and/or myocardial infarction. 
Depression was defined by the use of antidepressant drugs at the time of the interview.
Total cholesterol was determined by the enzymatic colorimetric method; high-density cholesterol (HDL-C) 
was determined by the homogeneous colorimetric method without precipitation, and triglycerides were deter-
mined by glycerol-phosphate peroxidase (ADVIA 1200 Siemens Deerfield, IL, USA). We used the total choles-
terol/HDL-C ratio as a covariate25.
Statistical analysis. The statistical analysis was accomplished using STATA™ software (Stata Corporation, 
College Station, TX, USA), v. 14.0. The categorical variables were described as frequencies and percentages. The 
continuous variables were described by the means and standard deviations (SDs) or medians and interquartile 
ranges, according to the normality of data definition, which was tested in histograms, and coefficients of asym-
metry (skewness) and kurtosis. In the univariate analysis, Pearson and Spearman’s correlations were used for the 
continuous variables with normal and non-normal distributions, respectively, to assess the correlation between 
the potential factors and cognitive performance. To compare means and medians from the cognitive tests among 
the potential associated factors, we used Student’s t-test, the Mann-Whitney test, ANOVA or the Kruskal-Wallis 
test. All the variables with p < 0.20 in the univariate analysis were pre-selected for inclusion in the multivariate 
analysis. The Trail Making Test B had a skewed distribution; therefore, we used the natural logarithmic transfor-
mation (log-transformed).
Multiple linear regression (forward) was applied for response variables memory test, verbal fluency test (ani-
mals and letter F), and log-transformed Trail Making Test B to estimate the association between cognitive perfor-
mance and diabetes (yes/no). The data were adjusted for age (categorical), sex and education in model 1; for all 
model 1 variables plus hypertension, coronary disease, and depression in model 2; and for all model 2 variables 
plus physical activity, smoking, alcohol use, and total cholesterol/HDL-C ratio in model 3.
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Variables Total population N = 14,444
Demographics
Female n (%) 7,850(54.4)
Age (years), n (%)
35 a 44 3,233(22.4)
45 a 54 5,687(39.4)
55 a 64 4,036(28.0)







Word-list learning mean ± SD 21.1 ± 3.9
Word-list delayed recall median[IQ] 7 [6–8]
Word recognition test median[IQ] 10[9–10]
Memory (learning, recall and word recognition test) 37.7 ± 5.9
Phonemic verbal fluency test (letter F) mean ± SD 12.5 ± 4.5
Semantic phonemic test (animals) mean ± SD 18.5 ± 5.3
Trail-making test B median[IQ] 95[73–132]
Habits and comorbidities
























Markers of adiposity, and laboratorial tests
Body mass index,(kg/m2) 27.0 ± 4.7
Waist circumference (cm) 91.2 ± 12.8
A1c mmol/mol(%) 36.6 ± 12.0 (5.5 ± 0.96)
Fasting plasma glucose (mg/dl) 106.7 ± 29.2
Triglycerides (mg/dL) median[IQ] 114.0[81–166]
HDL-C (mg/dl) mean ± SD 56.7 ± 14.5
Total Col-HDL-C median[IQ] 3.9[3.2–4.6]
Table 1. Characteristics of the participants of the study- ELSA-Brasil (2008–2010). Note. Memory = word-list 
learning + word-list delayed recall + word recognition tests. Data are presented as mean ± SD, median [IQ] or n 
(%). N: number; %: percentage; SD: standard deviation; IQ: interquartile range. A1c: glycated hemoglobin; Total 
Col-HDL-C – total cholesterol/High density cholesterol ratio.
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Results
There were 14,444 participants in this study; 54% were female, and the mean age was 52.0 years (±9.1). The edu-
cation level was high; 52.8% of the participants had a university degree. The characteristics of the participants are 
depicted in Table 1: 76.7% were sedentary, 57.0% never smoked, 63.1% were overweight (BMI 25.0–29.9 kg/m2), 
and 22.8% were obese (BMI ≥ 30.0 kg/m2). In the univariate analysis, there was an association between a worse 
cognitive performance in all cognitive tests and the highest age group, decreased schooling and smoking. The var-
iables with p < 0.2 in the univariate analysis were maintained in the multivariate analyses: hypertension, physical 
activity, alcohol use, coronary disease, and the total cholesterol/HDL-C ratio.
Table 2 shows the result of the linear regression between the memory tests (learning, recall and word recog-
nition tests) and diabetes. In the final model, we found that a lower cognitive performance was associated with 
diabetes. The results also showed better cognitive performance in women, and poor cognitive performance was 
associated with increased age, decreased schooling, smoking, moderate consumption of alcohol, and increased 
total cholesterol/HDL-C ratio. In Tables 3 and 4, we present the results of the linear regression analysis between 
verbal phonemic fluency (letter F), semantic phonemic test (animals) and diabetes. In this executive domain, the 
final model shows a worse cognitive performance with diabetes. Decreased cognitive performance was associated 
with increased age, among men, with decreased education, hypertension, depression, smoking and decreased 
physical activity levels.
Therefore, diabetes was associated with a decreased cognitive performance in the memory tests (learning, 
recall and word recognition tests) (β −0.53 [−10.77; −0.29] adjusted R2 0.21). The verbal fluency test (letter F) 
performance was decreased among patients with diabetes (β −0.50 [−0.69; −0.31] adjusted R2 0.18) and seman-
tic phonemic test (animals) also was decreased among patients with diabetes (β −0.27[−0.50; −0,04] adjusted R2 
0.21), although the magnitude of the association decreased slightly after all adjustments. Finally, an association 
was found between diabetes and the Trail Making Test B (eβ1.03 [1.02; 1.06] adjusted R2 0.30), after adjustments 
(Table 5). Therefore, in the final model, decreased cognitive performance was demonstrated in men, older indi-
viduals, patients with low education levels, hypertensive individuals and those who smoke.
Discussion
At baseline in this large Brazilian cohort with relatively young participants (52.0 ± 9.1 years old), an association 
between cognitive performance in the domains of memory (learning, recall and word recognition tests), pho-
nemic verbal fluency tests (letter F and animals), trail making and diabetes has been shown. This association 
occurred independently of education and other traditional risk factors (such as lipid levels), comorbidities (such 
as hypertension), and health-related behaviours (such as smoking).
Variable
Memory test (learning, recall and word recognition test)
Model 1 β[CI 95%] R20.21 Model 2 β[CI 95%] R20.21 Model 3 β[CI 95%] R20.22
Final Model β[CI 95%] 
R20.21
Diabetes −0.58 [−0.82, −0.34]*** −0.58 [−0.82, − 0.34]*** −0.57 [−0.82, − 0.31]*** −0.53 [−0.77, − 0.29]***
Age (years)
   35 a 44 1 1 1 1
   45 a 54 −0.75 [−0.98, −0.51]*** −0.75 [−0.98, −0.51]*** −0.60 [−0.84, −0.35]*** −0.64 [−0.87, −0.40]***
   55 a 64 −1.78 [−2.03, −1.52]*** −1.78 [−2,03–1.52]*** −1.68 [−1.96, −1.41]*** −1.68 [−1.94, −1.42]***
   65 a 74 −3.70 [−4.04, −3.36]*** −3.70 [−4.02, −3.36]*** −3.63 [−3.99, −3.26]*** −3.65 [−3.99, −3.31]***
Female sex 2.07 [1.90,2.25]*** 2.07 [1.90, 2.25]*** 2.08 [1.87, 2.28]*** 2.00 [1.81, 2.20]***
Education
Incomplete fundamental 1 1 1 1
   Complete fundamental 2.23[1.71,2.75]*** 2.23[1.71,2.75]*** 2.27[1.75,2.80]*** 2.20[1.68,2.71]***
   High schoool 4.30[3.88,4.72]*** 4.30[3.88,4.72]*** 4.22[3.79,4.66]*** 4.22[3.80,4.65]***
   University degree 7.21[6.80,7.63]*** 7.22[6.80,7.63]*** 7.09[6.66,7.52]*** 7.06[6.65,7.47]***
Smoking
   No 1 1
   Former −0.46 [−0.67, −0.25]*** −0.45 [−0.65, −0.24]***
   Current −0.90 [−1.19, −0.62]*** −0.88 [−1.16, −0.61]***
Alcoho l (g/week)
   1–175 1 1
   176–350 0.68[0.31, 1.06]*** 0.66[0.29, 1.03]**
   >350 0.61[−0.03, 1.19] * 0.42[−0.15, 0.98]
Total Col-HDL-C −0.13[−0.22, −0.04]** −0.15 [−0.24, −0.06]***
Table 2. Multivariate regression final models with memory function test and diabetes in ELSA-Brasil (baseline 
2008–2010) n = 14,444. Note. Total Col-HDL-C-Total cholesterol/High density cholesterol ratio. β[CI95%] 
– coefficient β and 95% confidence interval; R2-R2 adjusted. Model 1- Adjustment by age, sex and education, 
Model 2 - Model 1 plus hypertension, coronary disease and depression. Model 3 - Model 2 plus physical activity, 
smoking, alcohol use, total cholesterol / HDL-C. *p < 0.05; **p < 0.01; ***p < 0.001 Final models included 
variables with p < 0.05.
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Previous cross-sectional and longitudinal studies have focused on the substantial epidemiological evidence 
suggesting that diabetes is associated with cognitive impairment5,7. What is unclear is whether there is a specific 
pattern for impaired function in terms of the affected cognitive domains26. Many researchers have described an 
association between diabetes and cognitive performance in studies in Asia, North America and Europe2,10,25,27,28. 
However, the majority of studies in developed countries have been conducted in cohorts of patients over 60 years 
old and focused on cognitive diagnoses of conditions such as mild cognitive impairment and dementia2,4,10,28.
The influence of diabetes on cognitive performance among young and middle-aged adults, such as the partic-
ipants in the ELSA-Brasil cohort at baseline, is not well understood, especially in middle- and low-income coun-
tries. Our findings show associations between diabetes and cognitive performance in Brazilian individuals, where 
demographic and nutritional changes are increasing the prevalence of metabolic risk factors and threatening to 
accelerate the incidence of diabetes and neurodegenerative diseases29.
At the present study, diabetes had a significant impact on the performance of memory, phonemic verbal flu-
ency and Trail B tests. In a prospective Dutch study, cognitive performance was measured twice over a five-year 
interval in 2,613 individuals aged 43–70 years at baseline (1995–2002). They evaluated changes in cognitive per-
formance of individuals with previous or incident diabetes and compared global cognitive performance and 
specific domains of cognitive function (memory, speed, and cognitive flexibility) among individuals with and 
without type 2 diabetes. The results showed a decline in global cognitive function in individuals with diabetes that 
was 2.6 times greater than that in subjects without the disease. Interestingly, the magnitude of cognitive decline in 
most of the different domains was intermediate in subjects with incident diabetes in comparison with individuals 
without diabetes or individuals with diabetes that was prevalent at the study baseline. The results of this study 
seem to indicate that diabetes affects different domains of cognitive functioning at different stages of the disease 
process30.
Previous analysis of this Brazilian cohort has found that education plays a greater role than age in performance 
on cognitive tests31. High education levels were the strongest predictor of maintained cognitive function accord-
ing to different authors32,33. In this study, the impact of education on cognitive performance remained higher than 
the impact of diabetes, age, and other characteristics.
Variable
Phonemic verbal fluency (letter F)
Model 1 β[CI 95%] R20.17 Model 2 β[CI 95%] R20.18 Model 3 β[CI 95%] R20.18 Final Model β[CI 95%] R20.18
Diabetes −0.57[−0.75, −0.38]*** −0.52[−0.71, −0.33]*** −0.53[−0.72, −0.33]*** −0.50[−0.69, −0.31]***
Age (years)
   35 a 44 1 1 1 1
   45 a 54 −0.33[−0.51, −0.15]*** −0.30[−0.49, −0.12]*** −0.38[−0.57, −0.20]*** −0.37[−0.56, −0.19]***
   55 a 64 −0.81[−1.00, −0.61]*** −0.71[−0.91, −0.50]*** −0.83[−1,04–0.63]*** −0.85[−1.05, −0.65]***
   65 a 74 −1.36[−1.62, −1.10]*** −1.26[−1.53, −0.99]*** −1.38[−1.66, −1.11]*** −1.37[−1.63, −1.10]***
Female sex 0.13 [−0.01,0.27] 0.11 [−0.03, 0.25] 0.18 [0.03, 0.33]* 0.14 [0.01, 0.28]*
Education
   Incomplete fundamental 1 1 1 1
   Complete fundamental 1.58[1.20,1.96]*** 1.52[1.13,1.90]*** 1.50[1.11,1.89]*** 1.57[1.19,1.95]***
   High school 3.57[3.26,3.88]*** 3.56[3.25,3.87]*** 3.52[3.21,3.84]*** 3.54[3.23,3.85]***
   University degree 5.83[5.53,6.13]*** 5.80[5.49,6.10]*** 5.76[5.45,6.07]*** 5.77[5.46,6.07]***
Hipertension
   No 1 1 1
   Yes −0.35[−0.50, −0.20]*** −0.34[−0.50, −0.19]*** −0.33[−0.48, −0.18]***
Depression
   No 1 1 1









Table 3. Final models of multivariate regression with phonemic verbal fluency test (letter F) and diabetes in 
ELSA-Brasil (baseline 2008–2010) n = 14,444. Note. β[CI95%] – coefficient β and 95% confidence interval; R2-
R2 adjusted. Model 1- Adjustment by age, sex and education. Model 2 - Model 1 plus hypertension, coronary 
disease and depression. Model 3 - Model 2 plus physical activity, smoking, alcohol use, total cholesterol/HDL-C. 
*p < 0.05; **p < 0.01; ***p < 0.001 Final models included variables with p < 0.05.
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In the final model relating diabetes and memory tests (learning, recall and word recognition tests), phonemic 
verbal fluency tests (letter F and animals) and the Trail Making Test B, women presented with better cognitive 
performance than men, some resemblance to the results found in a German study with middle-aged partici-
pants34. We found an association between diabetes and cognitive performance, mainly in the domains of memory, 
attention, concentration, psychomotor speed and executive function. A meta-analysis examining the nature and 
magnitude of cognitive deficits in individuals with type 2 diabetes was performed to determine the magnitude 
of the Cohen effect (d) on the cognitive dysfunction of individuals with or without diabetes. The Cohen effect 
is characterised by differences in the standardised means between the experimental and comparison groups, 
divided by the standard deviation. The effect size “d” is characterised as small (0.2–0.3), medium (0.4–0.7) and 
large (≥0.8)35. In the meta-analysis, which included 24 studies, a total of 26,137 patients (n = 3,351 with dia-
betes) met the inclusion criteria. The domains studied were verbal memory (15 studies, n = 4,608, d = −0,28), 
visual memory (6 studies, n = 1,754, d = −0,26), attention and concentration (14 studies, n = 23,143; d = −0,19), 
processing speed (16 studies, n = 3,076, d = −0.33), executive function (12 studies, n = 1,784, d = −0.33) and 
motor function (3 studies, n = 2,374, d = −0.36). The following tests showed the most noticeable performance 
decreases in samples from patients with diabetes: Rey Auditory Verbal Learning Test (immediate) (d = −0.40), 
Trail Making Test B (d = −0.39) and the Stroop Part I (d = −0.28)36.
To date, insulin has been considered to have neuromodulatory effects that promote the plasticity of syn-
apses37. The impairment of insulin signalling, the presence of chronic inflammation and hyperglycaemia, the 
accumulation of advanced glycation end-products (AGEs) and increases in oxidative stress play an essential 
role in the pathogenesis of both diabetes and Alzheimer’s disease38,39. Inflammatory cytokines produced by 
macrophages and adipocytes may cross the blood-brain barrier and activate stress kinases, inducing insulin 
resistance. Moreover, amyloid β protein oligomers can indirectly contribute to brain insulin resistance through 
the microglial induction of kinases. Neuronal insulin resistance impairs synaptic function and contributes 
to the neurodegenerative process40. In a sample of 998 non-diabetic participants from a subanalysis of the 
ELSA-Brasil study, an association between a cluster of selected inflammatory biomarkers and poor cognitive 
scores was also demonstrated in middle-aged women41. Micro- and macrovascular disease and unstable meta-
bolic control in individuals with diabetes, including severe hypoglycaemic events, are also critical for cognitive 
changes 1,12.
Furthermore, the loss of brain volume has been described in patients with diabetes, particularly in regions of 
the hippocampus, thalamus, and cerebellar area42. Meta-analysis identified reduced resting-state brain activity in 
all brain regions in individuals with type 2 diabetes43. Although cognitive dysfunction is still not considered to 
Variable
Semantic phonemic test (animals)
Model 1 β[CI 95%] R20.22 Model 2 β[CI 95%] R20.21 Model 3 β[CI 95%] R20.21 Final Model β[CI 95%] R20.21
Diabetes −0.35[−0.56, −0.14]** −0.27[−0.50, −0.33]* −0.30[−0.53, −0.06]* −0.27[−0.50, −0.04]*
Age (years)
   35 a 44 1 1 1 1
   45 a 54 −0.73[−0.94, −0.53]*** −0.72[−0.94, −0.50]*** −0.77[−0.99, −0.55]*** −0.75[−0.96, −0.53]***
   55 a 64 −1.61[−1.83, −1.39]*** −1.54[−1.78, −1.30]*** −1.60[−1,84–1.35]*** −1.56[−1.80, −1.32]***
   65 a 74 −2.32[−2.62, −2.03]*** −2.21[−2.55, −1.88]*** −2.28[−2.61, −1.94]*** −2.21[−2.54, −1.89]***
Female sex 0.06 [0.10,0.21] 0.12 [−0.05, 0.28] 0.22 [0.04, 0.41]** 0.17 [0.01, 0.34]*
Education
   Incomplete fundamental 1 1 1 1
   Complete fundamental 1.36[0.93,1.79]*** 1.27[0.78,1.75]*** 1.28[0.79,1.76]*** 1.30[0.83,1.76]***
   High school 3.45[3.10,3.80]*** 3.35[2.97,3.75]*** 3.37[2.98,3.77]*** 3.37[2.99,3.75]***
   University degree 6.88[6.53,7.22]*** 6.75[6.37,7.13]*** 6.77[6.38,7.15]*** 6.77[6.39,7.14]***
Hipertension
   No 1 1 1
   Yes −2.82[−0.47, −0.10]** −0.30[−0.49, −0.11]** −0.28[−0.46, −0.10]**
Depression
   No 1 1 1





Table 4. Final models of multivariate regression with semantic phonemic test (animals) and diabetes in ELSA-
Brasil (baseline 2008–2010) n = 14,444. Note. β[CI95%] – coefficient β and 95% confidence interval; R2-R2 
adjusted. Model 1- Adjustment by age, sex and education. Model 2 - Model 1 plus hypertension, coronary 
disease and depression. Model 3 - Model 2 plus physical activity, smoking, alcohol use, total cholesterol/HDL-C. 
*p < 0.05; **p < 0.01; ***p < 0.001 Final models included variables with p < 0.05.
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be one of the main complications of diabetes, according to the current recommendations for good practice in the 
care of individuals with diabetes, it has become important to perform cognitive screening or cognitive assessment 
of these individuals13,44,45.
The strengths of this study include the large sample, methodological rigor in data collection, centralised anal-
ysis of the laboratory tests and quality assurance control. The use of this brief battery of neuropsychological tests 
was standardised and validated for the Brazilian population, thus increasing the reliability of the results17,46. In 
addition, a large set of covariables was evaluated, which allowed adjustment for a wide range of possible con-
founding factors. However, this study has some limitations. By its cross-sectional design, one cannot infer any 
causal relationship between cognitive performance and the associated variables. The investigation of the same 
variables in the follow-up of this cohort may add additional enlightening information. The ELSA-Brasil cohort 
has a much higher percentage of people with high education levels than the Brazil population. However, it is 
comparable to the cohorts of other international studies47. Moreover, we were unable to evaluate all cognitive 
tests for each domain, as is the case with large longitudinal studies of adult health in the world. Unfortunately, this 
comprehensive assessment is logistically impossible in the vast majority of cases.
Although Brazil has a distinct epidemiological profile, the observed associations between diabetes, cognitive per-
formance and metabolic risk factors are similar to those observed in cohorts in developed countries48,49. Preventive 
strategies may be more effective to avoid the worsening of cognition functions in these high-risk individuals50. Our data 
demonstrate that even a brief cognition evaluation is important in assessing the impact of diabetes on the mental health 
of this population, which may be of great relevance to many similar low- and middle-income countries. The ageing of 
our population will generate sharp increases in the number of older adults living with diabetes and, possibly, comorbid 
cognitive impairment. It is estimated, therefore, that the impaired treatment adherence and diabetes self-care represent 
a major challenge for future health systems around the world, particularly for those with fewer resources50.
In conclusion, we found a significant association between diabetes and cognitive function test performance in 
this relatively young and highly educated Brazilian population.
Data availability
The datasets generated during the current study are available from the corresponding author upon reasonable 
request.
Received: 28 May 2019; Accepted: 6 January 2020;
Published: xx xx xxxx
References
 1. Duron, E., & Hanon, O. Vascular risk factors, cognitive decline, and dementia. Vasc Health Risk Manag 4, 363–381, https://www.
ncbi.nlm.nih.gov/pmc/articles/PMC2496986/ (2008).
 2. Chatterjee, S. et al. Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million 
people comprising more than 100,000 cases of dementia. Diabetes Care 39, 300–307, https://doi.org/10.2337/dc15-1588 (2016).
Variable
Natural Log of the trail-making test B
Model 1 eβ [CI 95%] R2 0.29 Model 2 eβ [CI 95%] R2 0.29 Model 3 eβ [CI 95%] R2 0.30 Final Model eβ [CI 95%] R2 0.30
Diabetes 1.05[1.03,1.07]*** 1.03[1.01,1.05]** 1.03[1.01,1.05]*** 1.03[1.02,1.06]***
Age (years)
   35 a 44 1 1 1 1
   45 a 54 1.16[1.14,1.18]*** 1.15[1.14,1.18]*** 1.16[1.14,1.18]*** 1.16[1.14,1.18]***
   55 a 64 1.28[1.26,1.31]*** 1.27[1.24,1.29]*** 1.28[1.25,1.30]*** 1.28[1.26,1.31]***
   65 a 74 1.42[1.38,1.45]*** 1.38[1.34,1.42]*** 1.39[1.35,1.43]*** 1.40[1.37,1.44]***
Female sex 1.03[1.02,1.04]*** 1.03[1.02,1.04]*** 1.02[1.01,1.04]*** 1.03[1.02,1.04]***
Education
   Incomplete fundamental 1 1 1 1
   Complete fundamental 0.87[0.83,0.92]*** 0.87[0.82,0.91]*** 0.87[0.83,0.92]*** 0.88[0.83,0.92]***
   High school 0.68[0.65,0.70]*** 0.67[0.64,0.70]*** 0.67[0.64,0.70]*** 0.68[0.65,0.70]***
   University degree 0.49[0.47,0.51]*** 0.49[0.47,0.51]*** 0.49[0.46,0.51]*** 0.49[0.47,0.51]***
Hipertension
   No 1 1 1
   Yes 1.05[1.03,1.06]*** 1.04[1.03,1.06]*** 1.05[1.03,1.06]***
Smoking
   No 1 1
   Former 0.96[0.95,0.98]*** 0.96[0.95,0.98] ***
   Current 0.98[−0.96,1.00] 0.98[0.96,1.00]
Table 5. Final models of multivariate regression with log trail-making test B and diabetes in ELSA-Brasil 
(baseline 2008–2010) n = 14,444. Note. eβ – β exponential; [CI95%] – confidence interval 95%. Model 1- 
Adjustment by age, sex and education. Model 2 - Model 1 plus hypertension, coronary disease and depression. 
Model 3 - Model 2 plus physical activity, smoking, alcohol use, total cholesterol / HDL-C. *p < 0.05; **p < 0.01; 
***p < 0.001 Final models included variables with p < 0.05.
9Scientific RepoRtS |         (2020) 10:1596  | https://doi.org/10.1038/s41598-020-58332-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
 3. WHO- World Health Organization, https://www.who.int/ (2019).
 4. Zhao, X. et al. Biomarkers for cognitive decline in patients with diabetes mellitus: evidence from clinical studies. Oncotarget 9(7), 
7710–7726, https://doi.org/10.18632/oncotarget.23284 (2018).
 5. Kloppenborg, R. P. et al. Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review. Eur 
J Pharmacol 585, 97–108, https://www.ncbi.nlm.nih.gov/pubmed/18395201 (2008).
 6. Sims-Robinson, C., Kim, B., Rosko, A. & Feldman, E. L. How does diabetes accelerate Alzheimer disease pathology? Nat. Rev. Neurol 
6, 551–559, https://www.nature.com/articles/nrneurol.2010.130 (2010).
 7. Cukierman-Yaffe, T. et al. The Relationship Between the Score on a Simple Measure of Cognitive Function and Incident CVD in 
People With Diabetes: A Post Hoc Epidemiological Analysis From the ACCORD-MIND Study. J. Clin. Endocrinol. Metab. 102(9), 
3218–3225, https://doi.org/10.1210/jc.2016-3480 (2017).
 8. Macklin, L. et al. Glucose tolerance and insulin sensitivity are impaired in APP/PS1 transgenic mice prior to amyloid plaque 
pathogenesis and cognitive decline. Exp. Gerontology 88, 9–18, https://doi.org/10.1016/j.exger.2016.12.019 (2017).
 9. Avadhani, R. et al. Glycemia and cognitive function in metabolic syndrome and coronary heart disease. Am. J. Med. 128(1), 46–55, 
https://doi.org/10.1016/j.amjmed.2014.08.025 (2015).
 10. Palta, P. et al. Magnitude of Cognitive Dysfunction in Adults with Type 2 Diabetes: A Meta-analysis of Six Cognitive Domains and 
the Most Frequently Reported Neuropsychological Tests within Domains. J. Int. Neuropsychological Soc. 20, 278–291, https://doi.
org/10.1017/S1355617713001483 (2014).
 11. Berg, E. D., Kloppenborg, R. P., Kessels, R. C., Kappelle, L. J. & Biessels, G. J. Type 2 diabetes mellitus, hypertension, dyslipidemia 
and obesity: A systematic comparison of their impact on cognition. Biochimica et. Biophysica Acta 1792, 470–481, https://doi.
org/10.1016/j.bbadis.2008.09.004 (2009).
 12. Stoeckel, L. E. et al. Complex mechanisms linking neurocognitive dysfunction to insulin resistance and other metabolic dysfunction. 
REVIEW. F1000 Res. 5, 353, https://doi.org/10.12688/f1000research.8300.2 (2016).
 13. Munshi, M. N. Cognitive dysfunction in older adults with diabetes: what a clinician needs to know. Diabetes Care 40, 461–467, 
https://doi.org/10.2337/dc16-1229 (2017).
 14. Salas, A. et al. The Prevalence, Correlates, Detection and Control of Diabetes among Older People in Low and Middle Income 
Countries. A 10/66 Dementia Research Group Population-Based Survey. PLoS ONE 11, e0149616, https://doi.org/10.1371/journal.
pone.0149616 (2016).
 15. Lotufo, P. A. et al. Construction of the Longitudinal Study of Adult Health (ELSA-Brazil). Rev. Saude Publica 47(Suppl 2), 3–9, 
https://doi.org/10.1590/S0034-8910.2013047S20002 (2013).
 16. Aquino, E. et al. Brazilian Longitudinal Study of Adult Health (ELSA-Brasil): objectives and design. Am. J. Epidemiol. 175(4), 
315–24, https://doi.org/10.1093/aje/kwr294 (2012).
 17. Passos, V. M. A., Caramelli, P., Benseñor, I., Giatti, L. & Barreto, S. M. Methods Cognit. Funct. investigatiLongitud. Study Adult Health 
Sao Paulo Med. J. 132(3), 170–71, https://doi.org/10.1590/1516-3180.2014.1323646 (2014).
 18. Batista, J. A., Giatti, L., Barreto, S. M., Galery, A. R. P. & Passos, V. M. A. Reliability of Cognitive Tests of ELSA-Brasil, the Brazilian 
Longitudinal Study of Adult Health. Dement Neuropsychol 12;7(4), 367-373, https://doi.org/10.1590/S1980-57642013DN74000003 
(2013)
 19. Bertolucci, P. H. et al. Applicability of the CERAD neuropsychological battery to Brazilian elderly. Arq Neuropsiquiatr 59, 532-6, 
https://www.ncbi.nlm.nih.gov/pubmed/11588630 (2001)
 20. Machado, T. H. et al. Normative data for healthy elderly on the phonemic verbal fluency task FAS. Dement. Neuropsychologia 3(1), 
55–60, https://doi.org/10.1590/S1980-57642009DN30100011 (2009).
 21. Pellegrino Baena, C. et al. Migraine and cognitive function: baseline findings from the Brazilian Longitudinal Study of Adult Health: 
ELSA-Brasil. Cephalalgia. 38, 1525–1534, https://doi.org/10.1177/0333102417737784
 22. UNESCO. International Standard Classification of Education 1997, https://www.unesco.org/education/information/nfsunesco/doc/
isced_1997.htm. Acces 22 Sept. 2015
 23. Hallal, P. C. & Victora, C. Reliability and validity of the International Physical Activity Questionnaire (IP AQ) [letter]. Med Sci Sports 
Exerc 36 (3), 556, https://www.ncbi.nlm.nih.gov/pubmed/15076800 (2004)
 24. Schmidt, M. I. et al. Cohort profile: Longitudinal Study of Adult Health (ELSA-Brasil). Int J Epidemiol 44, 68-75, https://www.ncbi.
nlm.nih.gov/pubmed/24585730 (2004)
 25. Lemieux, I. et al. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart 
disease risk in men: the Quebec cardiovascular study. Arch InterMed 161, 2685‐2692, https://www.ncbi.nlm.nih.gov/
pubmed/11732933 (2001)
 26. Stewart, R. & Liolitsa, D. Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet. Med. 16(2), 93–112, https://doi.
org/10.1046/j.1464-5491.1999.00027.x (1999).
 27. Das, S. K. et al. An epidemiologic study of mild cognitive impairment in Kolkata, India. Neurology 68, 2019-26, https://www.ncbi.
nlm.nih.gov/pubmed/17548552/ (2007)
 28. Downer, B., Vickers, B. N., Al Snih, S., Raji, M. & Markides, K. S. Effects of Comorbid Depression and Diabetes Mellitus on 
Cognitive Decline in Older Mexican Americans. J Am Geriatr Soc 64, 109–17, https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC6130408/ (2016)
 29. Schmidt, M. I. et al. Cohort profile: Longitudinal Study of Adult Health (ELSA-BRASIL). Int. J. Epidemiol. 44(1), 68–75, https://doi.
org/10.1093/ije/dyu027 (2015).
 30. Nooyens, A. C., Baan, C. A., Spijkerman, A. M. & Verschuren, W. M. Type 2 diabetes and cognitive decline in middle-aged men and 
women: the Doetinchem Cohort Study. Diabetes Care 33, 1964-9, https://www.ncbi.nlm.nih.gov/pubmed/20519662 (2010)
 31. de Azeredo Passos, V. M. et al. Education plays a greater role than age in cognitive test performance among participants of the 
Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). BMCNeurology 15(1), 191, https://www.ncbi.nlm.nih.gov/
pubmed/26452731 (2015)
 32. Albert, M. S., Savage, C. R., Berkman, L., Seeman, T. & Rowe, J. W. Predictors of cognitive change in older persons: MacArthur 
Studies of Successful Aging. Psychol. and Aging 70, 578-589, https://www.ncbi.nlm.nih.gov/pubmed/8749585 (1995)
 33. Rowe, J. W. & Kahn, R. L. Successful aging. The Gerontologist 37, 433-440, https://www.ncbi.nlm.nih.gov/pubmed/9279031 (1997)
 34. Winkler, A. et al. Association of diabetes mellitus and mild cognitive impairment in middle-aged men and women. J Alzheimers Dis 
42, 1269–77, https://www.ncbi.nlm.nih.gov/pubmed/25024326 (2014)
 35. Cohen, J. Statistical Power Analysis for the Behavioral Sciences. (2 ed. New York) Lawrence Erlbaum Associates. 19–66 (1988)
 36. Berg, E. V. D., Kloppenborg, R. P., Kessels, R. P. C., Kappelle, L. J. & Biessels, G. J. Type 2 diabetes mellitus, hypertension, dyslipidemia 
and obesity: A systematic comparison of their impact on cognition. Biochimica et Biophysica Acta 1792, 470–481, https://www.ncbi.
nlm.nih.gov/pubmed/18848880 (2009)
 37. Ferrario, C. R. & Reagan, L. P. Insulin-mediated synaptic plasticity in the CNS; Anatomical, functional and temporal contexts. 
Neuropharmacology 12, 0-1, https://www.ncbi.nlm.nih.gov/pubmed/29217283 (2018)
 38. Duncan, B. B. et al. Low-grade systemic inflammation and the development of type 2 diabetes: the Atherosclerosis Risk in 
Communities study. Diabetes 52, 1799-1805, https://www.ncbi.nlm.nih.gov/pubmed/12829649 (2003)
 39. De Felice, F. G. & Ferreira, S. T. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular 
denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 63, 2262–2272, https://www.ncbi.nlm.nih.gov/
pubmed/24931033 (2014)
1 0Scientific RepoRtS |         (2020) 10:1596  | https://doi.org/10.1038/s41598-020-58332-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
 40. Simo, R., Ciudin, A., Simo-Servat, O. & Hernandez, C. Cognitive impairment and dementia: a new emerging complication of type 
2 diabetes. Acta Diabetol. 54, 417–424, https://www.ncbi.nlm.nih.gov/pubmed/28210868 (2017)
 41. Cezaretto, A. et al. Utility of combined inflammatory biomarkers for the identification of cognitive dysfunction in non-diabetic 
participants of the ELSA-Brasil. Psychoneuroendocrinology 103, 61–66, https://doi.org/10.1016/j.psyneuen.2019.01.003. Epub (2019)
 42. Roberts, R. O. et al. Association of type 2 diabetes with brain atrophy and cognitive impairment. Neurology 82, 1132–1141, https://
www.ncbi.nlm.nih.gov/pubmed/24647028 (2014)
 43. Macpherson, H., Formica, M., Harris, E. & Daly, R. M. Brain functional alterations in Type 2 Diabetes A systematic review of fMRI 
studies. Frontiers Neuroendocrinology 47, 34–46, https://www.ncbi.nlm.nih.gov/pubmed/28687473/ (2017)
 44. Biessels, G. J & Whitmer, R. A. Cognitive dysfunction in diabetes: how to implement emerging guidelines. Diabetologia Aug 16 
https://doi.org/10.1007/s00125-019-04977-9 (2019)
 45. ADA-American Diabetes Association (ADA). Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of 
Medical Care in Diabetes—2018. Diabetes Care 41(Supplement 1), S28–S37, https://doi.org/10.2337/dc18-S003 (2018).
 46. Passos, V. M. A. et al. Verbal fluency tests reliability in a Brazilian multicentric study, ELSA-Brasil. Arq Neuropsiquiatr 69, 814–816, 
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2011000600017 (2011)
 47. Luchsinger, J. A., Cabral, R., Eimicke, J. P., Manly, J. J. & Teresi, J. Glycemia, Diabetes Status, and Cognition in Hispanic Adults Aged 
55–64 Years. Psychosom. Med. 77, 653–63, https://doi.org/10.1097/PSY.0000000000000208 (2015).
 48. Xue, M. et al. Diabetes mellitus and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 144 
prospective studies. Ageing Research Reviews 55 https://doi.org/10.1016/j.arr.2019.100944 (2019)
 49. Zheng, F., Yan, L., Yang, Z., Zhong, B. & Xie, W. HbA1c, diabetes and cognitive decline: the English Longitudinal Study of Ageing. 
Diabetologia 61(4), 839–848, https://doi.org/10.1007/s00125-017-4541-7 (2018).
 50. Salas, A., Acosta, D., Guerra, M. & Huang, Y. Diabetes and dementia incidencia in Latin America; a 10/66 population-based cohort 
study. The preprint server for Biology. Jul, https://www.biorxiv.org/content/10.1101/148155v1 (2017)
Acknowledgements
The authors thank all participants and the staff of the ELSA-Brasil study for their important contributions. 
Statement of assistance: The authors give special thanks to Fernando Henrique Pereira for his statistical 
consultation.The ELSA-Brasil study was supported by the Brazilian Ministry of Health (Science and Technology 
Department) and the Brazilian Ministry of Science and Technology (Financiadora de Estudos e Projetos and 
CNPq National Research Council) (grants 01 060010.00 RS, 01 06 0212.00 BA, 01 06 0300.00 ES, 01 06 0278.00 
Mg, 01 06 0115.00 SP, 01 06 0071.00 RJ).
Author contributions
M.M.T. wrote the manuscript. M.M.T., V.M.A.P. and M.F.H.S.D. planned the study and analysed the data. 
V.M.A.P., S.M.B., M.I.S., B.B.D., A.M.R.B., P.G.V. and M.F.H.S.D. critically reviewed and edited the manuscript 
for important intellectual content. M.J.M.F. and L.F.A. helped with the statistical analysis of the data. All authors 
approved the final version of the manuscript. M.M.T. is the guarantor of this work.
competing interests
The authors declare no competing interests.
Additional information
Correspondence and requests for materials should be addressed to M.M.T.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2020
